Abstract
Alzheimer’s disease (AD) is characterized by amyloid plaques composed of the β-amyloid (Aβ) peptide surrounded by swollen presynaptic dystrophic neurites consisting of dysfunctional axons and terminals that accumulate the β-site amyloid precursor protein (APP) cleaving enzyme (BACE1) required for Aβ generation. The cellular and molecular mechanisms that govern presynaptic dystrophic neurite formation are unclear, and elucidating these processes may lead to novel AD therapeutic strategies. Previous studies suggest Aβ may disrupt microtubules, which we hypothesize have a critical role in the development of presynaptic dystrophies. To investigate this further, here we have assessed the effects of Aβ, particularly neurotoxic Aβ42, on microtubules during the formation of presynaptic dystrophic neurites in vitro and in vivo. Live-cell imaging of primary neurons revealed that exposure to Aβ42 oligomers caused varicose and beaded neurites with extensive microtubule disruption, and inhibited anterograde and retrograde trafficking. In brain sections from AD patients and the 5XFAD transgenic mouse model of amyloid pathology, dystrophic neurite halos with BACE1 elevation around amyloid plaques exhibited aberrant tubulin accumulations or voids. At the ultrastructural level, peri-plaque dystrophies were strikingly devoid of microtubules and replete with multi-lamellar vesicles resembling autophagic intermediates. Proteins of the microtubule motors, kinesin and dynein, and other neuronal proteins were aberrantly localized in peri-plaque dystrophies. Inactive pro-cathepsin D also accumulated in peri-plaque dystrophies, indicating reduced lysosomal function. Most importantly, BACE1 accumulation in peri-plaque dystrophies caused increased BACE1 cleavage of APP and Aβ generation. Our study supports the hypothesis that Aβ induces microtubule disruption in presynaptic dystrophic neurites that surround plaques, thus impairing axonal transport and leading to accumulation of BACE1 and exacerbation of amyloid pathology in AD.Electronic supplementary materialThe online version of this article (doi:10.1007/s00401-016-1558-9) contains supplementary material, which is available to authorized users.
Highlights
The β-amyloid (Aβ) peptide, the major component of amyloid plaques, has a crucial early role in Alzheimer’s disease (AD) pathogenesis [58]
We provide evidence that Aβ mediates microtubule disruption and microtubule-based transport impairment leading to dystrophic neurite formation, BACE1 accumulation, increased BACE1 cleavage of amyloid precursor protein (APP) and Aβ production
In the 5XFAD mouse model of amyloid pathology, presynaptic dystrophic neurites surrounding plaques showed BACE1 accumulation that correlated with aberrant localization patterns of tubulins, microtubule motor proteins, and synaptic and cell body proteins
Summary
The β-amyloid (Aβ) peptide, the major component of amyloid plaques, has a crucial early role in Alzheimer’s disease (AD) pathogenesis [58]. A mutation at the β′-site (E682K [87]) causes AD by shifting BACE1 cleavage toward β-site processing of APP and Aβ generation. These mutations and other evidence strongly support therapeutic BACE1 inhibition for AD [67]. BACE1 levels are elevated in AD brain [14, 18, 31, 80, 86] potentially necessitating high doses of BACE1 inhibitor drugs, increasing the risk of side effects. Lowering/normalizing BACE1 levels in AD brain rather than direct inhibition of enzyme activity offers an alternative therapeutic approach that could avoid BACE1 inhibitor side effects. Elucidating the mechanism of BACE1 elevation in AD is essential for developing BACE1 lowering strategies
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have